[Disclosure] SAMSUNG BIOLOGICS(207940) Amends Confidentiality Deadline to 2030 for European CMO LOI

Fact Source: Financial Supervisory Service DART / 2024-12-19

Disclosure Type: Major Management Matters Related to Investment Judgment (Amendment)

💡 3-Second Summary

SAMSUNG BIOLOGICS has amended the counterparty confidentiality expiration date of its 2022 biopharmaceutical contract manufacturing Letter of Intent (LOI) with a European pharmaceutical firm to December 31, 2030, at the customer’s request.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Reason for Amendment: Extension of the confidentiality deadline at the customer’s request.
• Amendments Made (Data Integrity Verification):
  • Contract Period Item: (Before Amendment) 2022.4.25 ~ 2024.12.31 ➔ (After Amendment) Deleted
  • Confidentiality Deadline: Changed from December 31, 2024 to December 31, 2030
  • Counterparty Disclosure Rule: Updated to be disclosed prior to December 31, 2030, the main contract expiration date.
• Core Contract Details:
  • Title: Execution of Letter of Intent (LOI) for Contract Manufacturing of Biopharmaceuticals
  • Counterparty: A pharmaceutical company located in Europe (Identity withheld until December 31, 2030, due to operational confidentiality).
  • Contract Value: KRW 154,093,728,300 (Confirmed total: USD 124,099,000)
    • Applied Exchange Rate: Fixed at the initial base rate of USD/KRW 1,241.70 as of April 25, 2022.
  • Ratio to Revenue at Initial Filing: 9.38% (Compared against the respective fiscal year’s revenue of KRW 1,568,006,928,039).
  • Key Timeline: LOI signed on April 25, 2022 / Board Resolution or Fact Verification Date: April 25, 2022 / Amendment Filing Date: December 19, 2024.
• Regulatory Note: The stated contract value carries binding legal force between both parties. A separate formal disclosure will be filed once the definitive main contract is executed.

📈 2. [Expert Insight: What This Disclosure Means for Investors]

This amendment filing, submitted on December 19, 2024, primarily updates the confidentiality period and does not change the disclosed LOI structure, ensuring data alignment within the public registry.

The primary fundamental point is that the underlying contract metrics remain unchanged. The contract value is maintained at the initially reported KRW 154.09B (USD 124.09M), and data validation shows that the ratio to historic revenue remains matched at 9.38%.

Simultaneously, the amendment updates the confidentiality period from the end of 2024 out to December 31, 2030. The document contains zero revisions to current balance sheet metrics, active production facility operations, or immediate CAPEX timelines. Because the filing does not detail any qualitative causes beyond the customer’s request for changing the dates, the contract process remains subject to future definitive disclosures.

📝 Editor’s Comment (by K-STOCK Editor)

SAMSUNG BIOLOGICS has processed an administrative amendment to its 2022 European LOI tracking ledger. According to the document filed on December 19, 2024, the contract value remains at approximately KRW 154.09B, and the confidentiality mask regarding the counterparty’s identity has been shifted to December 31, 2030.

For international investors, this amendment constitutes a mechanical alignment of disclosure parameters rather than a new immediate operational driver. The significance is restricted to the extension of the confidentiality period as requested by the client. The exchange rate from the initial disclosure date is applied as stated in the filing. As indicated in the regulatory notice, the definitive data will be publicized upon the execution of the main contract, meaning that the LOI remains subject to future definitive contract disclosures.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.